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Blood lipids are important cardiovascular disease (CVD) risk factors with both genetic and environmental determinants. The Whitehall
II study (n ¼ 5592) was genotyped with the gene-centric HumanCVD BeadChip (Illumina). We identiﬁed 195 SNPs in 16 genes/regions
associated with 3 major lipid fractions and 2 apolipoprotein components at p < 105, with the associations being broadly concordant
with prior genome-wide analysis. SNPs associated with LDL cholesterol and apolipoprotein B were located in LDLR, PCSK9, APOB,
CELSR2, HMGCR, CETP, the TOMM40-APOE-C1-C2-C4 cluster, and the APOA5-A4-C3-A1 cluster; SNPs associated with HDL cholesterol
and apolipoprotein AI were in CETP, LPL, LIPC, APOA5-A4-C3-A1, and ABCA1; and SNPs associated with triglycerides in GCKR, BAZ1B,
MLXIPL, LPL, and APOA5-A4-C3-A1. For 48 SNPs in previously unreported loci that were signiﬁcant at p < 104 inWhitehall II, in silico
analysis including the BritishWomen’s Heart and Health Study, BRIGHT, ASCOT, and NORDIL studies (total n > 12,500) revealed previ-
ously unreported associations of SH2B3 (p < 2.2 3 106), BMPR2 (p < 2.3 3 107), BCL3/PVRL2 (ﬂanking APOE; p < 4.4 3 108), and
SMARCA4 (ﬂanking LDLR; p < 2.5 3 107) with LDL cholesterol. Common alleles in these genes explained 6.1%–14.7% of the variance
in the ﬁve lipid-related traits, and individuals at opposite tails of the additive allele score exhibited substantial differences in trait levels
(e.g.,>1mmol/L in LDL cholesterol [~1 SD of the trait distribution]). These data suggest that multiple common alleles of small effect can
make important contributions to individual differences in blood lipids potentially relevant to the assessment of CVD risk. These genes
provide further insights into lipid metabolism and the likely effects of modifying the encoded targets therapeutically.Introduction
LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), and
triglycerides (TG) are correlated phenotypes inherited as
complex traits. Their measurements are used clinically to
evaluate risk of future cardiovascular disease (CVD)3,4
and to guide prescription of statin drugs for primary
prevention. Whereas LDL-C and apolipoprotein (apo) B,
which are lowered by statins, have been shown to play
a causal role in atherosclerosis,5 the causal relevance of
the other lipid-related traits is currently uncertain. ApoAI
is the major protein moiety of HDL-C, and more recently
it has been suggested that the ratio of apoB/apoAI,
representing the balance between proatherogenic apoB-
containing particles and the antiatherogenic apoAI-con-taining particles, is among the strongest predictor of
CVD risk.6
To date, genome-wide association studies (GWAS) have
been successful in identifying 22 genes/regions associated
with blood lipids, although they contribute only 3%–5%
of the total variance of LDL-C, HDL-C, and TG,7 but less
information is available on the genetic determinants of
apoB and apoAI. Many of these GWAS discoveries recon-
ﬁrm previously validated lipid-related genes, though
substantial new insight into pathways relevant to lipid
metabolism has been provided by identiﬁcation of hith-
erto unsuspected genes.7 Intervals of association discov-
ered in GWAS studies have often been large and may
contain more than one annotated gene, and so the
identity, mechanism, and number of causal sites remains1Centre for Cardiovascular Genetics, 2Centre for Clinical Pharmacology, Department of Medicine, University College London, London WC1E 6JF, UK;
3Department of Genetics, Environment and Evolution, Genetics Institute, 4Wolfson Institute of Biological Research, 5Genetic Epidemiology Group, Depart-
ment of Epidemiology and Public Health, University College London, LondonWC1E 6BT, UK; 6Department of Epidemiology and Population Health, Lon-
don School of Hygiene and Tropical Medicine, London WC1E 7HT, UK; 7MRC Centre for Causal Analyses in Translational Epidemiology, Department of
Social Medicine, University of Bristol, Oakﬁeld House, Oakﬁeld Grove, Bristol BS8 2BN, UK; 8Clinical Pharmacology and Barts and the London Genome
Centre, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK;
9BHF Glasgow Cardiovascular Research Centre, Division of Cardiovascular and Medical Sciences, University of Glasgow, Western Inﬁrmary, Glasgow
G12 8TA, UK; 10Department of Cardiovascular Sciences, University of Leicester, Glenﬁeld Hospital, Leicester LE3 9QP, UK; 11International Centre for Circu-
latory Health, National Heart & Lung Institute, Imperial College London, London W2 1NY, UK; 12Molecular and Cellular Therapeutics, Royal College of
Surgeons in Ireland, Dublin 2, Ireland; 13Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin 4, Ireland; 14For full
details, see ref. 1; 15Clinical Research Center (CRC), Malmo¨ University Hospital, Malmo¨ SE-205 02, Sweden; 16For full details, see ref. 2; 17For the full author
list, see the Appendix
*Correspondence: john.whittaker@lshtm.ac.uk
DOI 10.1016/j.ajhg.2009.10.014. ª2009 by The American Society of Human Genetics. All rights reserved.
628 The American Journal of Human Genetics 85, 628–642, November 13, 2009
uncertain for the most part. SNP arrays utilized for GWAS
have been designed primarily for broad coverage of the
genome, and are therefore not ideal tools for identiﬁcation
of causal variants or resolution of independent signals
within these intervals of association. Studies with dense
SNP coverage may uncover additional independently asso-
ciated variants at known loci, and also at previously
unknown loci not well covered by GWAS studies, both of
which may contribute to some of the remaining unex-
plained variance.
For many genes identiﬁed by whole-genome analysis,
such as the association of CELSR2 (MIM 604265) locus
with LDL-C,8,9 replication efforts have rightly focused on
a subset of the most strongly associating SNPs, rather
than on capturing the full genetic architecture of the
region. It has been proposed that a gene-centric SNP array
that includes SNP content from many of the genes or
regions identiﬁed by GWAS, as well as additional candidate
genes, could help reﬁne association signals in a gene or
region to help delineate independently associated variants
that better mark or represent causal sites.
The Human CVD Beadchip (Cardiochip) was developed
in part for this purpose, and a small multiethnic study
examining the association of lipid traits with the same
array has been published recently, but reported only four
gene-lipid trait associations.10 We have used this gene-
centric SNP array (incorporating content from GWAS and
candidate gene studies, animal models of hyperlipidaemia
and atherosclerosis, and prior biological knowledge)11 in
a large prospective observational study of middle-aged civil
servants (Whitehall II; WH-II).12
The design of the Cardiochip included three levels of
coverage. Group 1 loci (genes and regions with a high like-
lihood of functional signiﬁcance, including established
mediators of vascular disease, loci derived from GWAS,
and those shown to be associated with phenotypes of
interest) had average coverage of 36 SNPs per locus,
a higher density of coverage than for the SNP arrays used
for the majority of GWAS reported to date. Group 2 loci
(deﬁned as candidate loci that are potentially involved in
phenotypes of interest or established loci that required
very large numbers of tagging SNPs) had average coverage
of 16.3 SNPs/locus, similar to that of the most widely used
whole-genome SNP arrays, whereas Group 3 loci com-
prised rarer nonsynonymous SNPs and those with estab-
lished functionality with MAF > 0.01.11
Our aim was to identify genes and regions associated
with LDL-C and HDL-C and TG, and we extend these asso-
ciations to their protein components, apoB and apoAI, in
order to assess the extent to which associations may over-
lap across traits, and to identify a subset of independently
associated variants at each region. To validate previously
unreported associations, we undertook a pooled in silico
analysis in the British Women’s Heart and Health Study
(BWHHS),13 the British Genetics of Hypertension
(BRIGHT)14 study, the UK subgroup from the Anglo-
Scandinavian Cardiac Outcomes Trial (ASCOT),1 and theThe AmericanNORDIL Study,2 and we performed further validation in
the Northwick Park Heart Study II (NPHSII).15
Material and Methods
Whitehall II Study
TheWhitehall II study (WH-II) recruited 10,308 participants (70%
men) between 1985 and 1989 from 20 London-based Civil service
departments.16 Blood samples for DNA were collected in 2002–
2004 from more than 6000 participants. Total cholesterol,
HDL-C, and TG were measured within 72 hr in serum stored at
4C via standard enzymatic colorimetric methods in the same
laboratories with identical methodology for all subjects. LDL-C
concentration was calculated with the Friedewald formula.17
ApoAI and apoB levels were determined by immunoturbidime-
try.18 Details of the design, participants, lipid measurements,
and genotyping of WH-II are presented in Table S1 (available
online) together with summary details of the four other studies
contributing to the replication phase of the analysis. The study
was approved by the UCL Research Ethics Committee, and partic-
ipants gave informed consent to each aspect of the study.
Genotyping and Quality Control
DNA fromWH-II was extracted from 6156 individuals fromwhole
blood samples (via magnetic bead technology; Medical Solutions,
Nottingham, UK) and normalized to a concentration of 50 ng/ml.
We used custom SNP arrays designed by the Institute of Transla-
tional Medicine and Therapeutics, the Broad Institute, and the
National Heart Lung and Blood Institute supported Candidate-
gene Association Resource Consortium (HumanCVD BeadChip;
Illumina)11 on 5592 of these samples (this included 115 samples
that were run as hidden duplicates). The initial genotype calls
were generated with the cluster ﬁle provided by Illumina Beadstu-
dio software. Call frequencies were below 98% for 1,798 out of the
49,094 SNPs. These were reviewed by eye and reclustered manu-
ally. SNPs that remained below 98% after reclustering were dis-
carded.113 duplicate pairs had a concordance rate >99.5%, 1
pair had a concordance rate of 99.1%, and 1 pair had a concor-
dance rate of 95%. Manual reclustering of some SNPs resulted in
duplicate concordance rates of 100%. 5557 samples passed the
prespeciﬁed sample call rate threshold of 80%. Removing 115
duplicates and 1 sample of ambiguous identity left 5441 samples
of which 5067 were whites. Eight outliers from the principal
component analysis were removed based on the genome-wide
identity-by-state analysis implemented in PLINK (see Figure S1),
leaving 5059 samples for further analysis. 48,032 SNPs with call
rates greater than 0.98 were included in the ﬁnal analysis marker
set in 5059 individuals of white ancestry. The genomic inﬂation
factors for all the analyses reported were close to 1, indicating
negligible inﬂuence from population structure or genotyping
errors.
Summary Demographics
DNA extraction methods, genotyping, and QC ﬁlters for the other
participating studies are detailed in Table S1. Forty-eight SNPs
identiﬁed inWH-II were exchanged with the prospective BWHHS,
and three studies of hypertensive cohorts, BRIGHT, ASCOT,
and NORDIL. These cohorts provided in silico results with the
same analysis plan as performed in WH-II. Two of these SNPsJournal of Human Genetics 85, 628–642, November 13, 2009 629
(rs3184504 and rs1049817) were directly genotyped in NPHSII
(n ¼ 3052). All results were pooled by a ﬁxed effect meta-analysis.
Statistical Analyses
Significance
We applied an additive genetic model in PLINK19 and used the
corresponding p values to construct quantile-quantile and
Manhattan plots. We adopted a conservative p value of 1 3 105
for declaration of signiﬁcance. The signiﬁcance threshold repre-
sented a trade-off between avoidance of false positive associations
while taking into account the likely higher prior odds of associa-
tion because of the nature of the array. The Bonferroni correction
for the 50,000 SNPs is 106 for 50,000 independent tests with no
prior information. Our cut-off was set to a more relaxed 105
because the prior odds that some of the SNPs tested would be asso-
ciated with the phenotypes tested was higher than for a whole-
genome array. Under the global null of no true associations,
104 would give an expected number of false positives of 5 for
each independent phenotype. However, SNPs crossing a lower
p value threshold of 1 3 104 were further analyzed in silico in
BWHHS, BRIGHT, ASCOT, and NORDIL and the results pooled
by a ﬁxed effect meta-analysis of individual study beta coefﬁcients,
weighted by the inverse of the variance, via the metafor library in
R. All results presented are from analyses adjusted for gender and
age, the latter treated as a categorical variable with 5-year bands
(39–44, 45–49, 50–54, 55–59, 60–65 in WH-II). Analyses were
not adjusted for use of lipid-lowering drugs because the prevalence
was generally low; of the 5059 individuals from WH-II, 39 (0.8%)
were taking lipid-lowering medication at the time of lipid
measurement. The proportion of subjects receiving lipid-lowering
medication at the time of blood sampling varied between 0% and
12.6% in BWHHS, BRIGHT, ASCOT, and NORDIL (Table S1).
Independence of Association Signals
To assess the best genetic predictors at each locus, a variable selec-
tion algorithm was implemented as follows. SNPs were ﬁltered
according to whether they reached the p value cut-off of 105 in
the univariate analyses and had a MAF > 0.001. The set of markers
thus obtained was augmented for any missing genotype data with
the software fastPHASE,20 and a stepwise selection scheme with
the Akaike’s Information Criterion (AIC)21 was implemented sepa-
rately for each chromosome. The genetic model assumed an addi-
tive effect on the appropriate scale, adjusting for gender and age as
in the univariate analyses.
Effect Size
We ﬁrst assessed the proportion of the trait variance explained by
SNPs both singly and in combination. The estimates for the
proportion of the total trait variance explained (R2) were obtained
by the regression of the SNP on the trait of interest without adjust-
ment for covariates as well as for the covariates separately. To
obtain the R2 for all loci showing signiﬁcant association with the
trait, we used SNPs selected from the stepwise regression (variable
selection), and a linear model was ﬁtted between age, gender, and
the trait. The residuals of this model were then used to obtain the
percentage of residual variance in the trait explained by all the
SNPs characterizing a single gene or a gene cluster. We separately
assessed the effect size as the beta coefﬁcient of the linear regres-
sion of individual SNPs on trait level by using a per-allele model.
Finally, to assess the joint effect of carriage of multiple indepen-
dently associated SNPs, we developed a gene score and computed
the odds of lying within the 10% tail of the risk factor distribution,
based on the centile position in the frequency distribution of gene630 The American Journal of Human Genetics 85, 628–642, Novemscore values. The gene score, based on SNPs remaining in the
model for the trait after variable selection, were recoded with the
allele having the detrimental effect as 1 and the other as 0, and
each individual was assigned a score of 0, 1, or 2 according to their
genotype for each SNP. The simple unweighted version of the gene
score was calculated by summing the scores across all relevant
SNPs for each individual. The alternative approach of weighting
each SNP score by the relevant beta coefﬁcient yielded very similar
ﬁndings (data not shown) and the simpler model is presented
here.
Results
The anthropometric characteristics and lipid and lipopro-
tein proﬁles of the 5059 white men and women from
WH-II after QC are presented in Table 1. A total of 195
SNPs with a MAF > 0.001 and Hardy-Weinberg p values >
0.0001 were found to be associated with one or more of
LDL-C, HDL-C, TG, apoB, or apoAI at a prespeciﬁed signif-
icance level of p < 105. These SNPs encompassed 16 gene
regions (Figure 1) and were robust to adjustment for age
and gender (Table S2).
Validation of Signals at Previously Reported Loci
for Blood Lipids and Effects on ApoB and ApoAI
We identiﬁed 60 SNPs in 12 genes/clusters associated with
LDL-C (Table S3A) and 53 SNPs in 9 genes/clusters associ-
ated with apoB (Table S3B). These included multiple strong
associations for LDL-C and apoB, respectively, of SNPs in
LDLR (MIM 606945) (rs17248720, p ¼ 7.9 3 1025 and
p ¼ 2.1 3 1015), PCSK9 (MIM 607786) (rs11591147, p ¼
9.0 3 1012 and p ¼ 2.0 3 1010), and APOB (MIM
Table 1. Lipid and Anthropometric Characteristics of the
Whitehall-II Participants Taken at Phase 3
Trait Men n ¼ 3720 Women n ¼ 1338
Mean SD Mean SD
Age (yrs) 49.06 5.94 49.59 6.10
BMI (kg/M2) 25.03 3.08 25.31 4.70
Hip (cm) 96.88 6.14 97.03 9.53
Waist (cm) 87.15 9.16 74.41 11.59
DBP (mmHg) 80.72 8.92 76.14 9.31
SBP (mmHg) 121.52 12.77 116.64 13.65
Chol (mmol/l) 6.45 1.11 6.43 1.17
LDL-C (mmol/l) 4.43 0.99 4.199 1.07
ApoB (g/L) 1.30 0.29 1.19 0.30
TG (mmol/l) 1.55 1.20 1.13 0.69
HDL-C (mmol/l) 1.33 0.35 1.72 0.43
ApoA1 (g/L) 2.06 0.32 2.35 0.38
Abbreviations: SD, standard deviation; BMI, body mass index; DBP, diastolic
blood pressure; SBP, systolic blood pressure; chol, cholesterol; LDL-C, low-
density lipoprotein cholesterol; ApoB, apolipoprotein B; TG, triglycerides;
HDL-C, high-density lipoprotein cholesterol; ApoAI, apolipoprotein AI.ber 13, 2009
Figure 1. Manhattan Plots Showing the Associations of 48,032 SNPs by Chromosome for the 5 Lipid and Apolipoprotein Phenotypes
versus –log10 p Value
The horizontal line indicates a p value threshold of 105. The Quantile/Quantile plots for the test statistics of the observed association p
values plotted as a function of the expected SNP; association p values are inset for each trait. *SNPs with MAF< 0.001 but with p< 105.107730) (rs563290, p ¼ 1.3 3 1011 and p ¼ 7.0 3 1013).
We also identiﬁed multiple signals of association in
a region of chromosome 19 that includes the TOMM40
(MIM 608061)-APOE (MIM 107741)-C1 (MIM 107710)-
C2 (MIM 608083)-C4 (MIM 600745) gene cluster, and
which, because of the extensive tagging in the Cardiochip,
extended nearly 60 kb upstream to include SNPs in BCL3
(MIM 109560) and PVRL2 (MIM 600798) (Table S6). In
addition, SNPs in LD with previously reported LDL-C-
related SNPs in CELSR2 (rs12740374 and rs629301),22
HMGCR (MIM 142910) (rs12916),9,22 and CETP (MIM
118470) (rs3764261)23,24 also exhibited signiﬁcant associ-
ations with both LDL-C and apoB. Highly signiﬁcant asso-
ciations with apoB (but not LDL-C) were observed for SNPs
within the APOA5 (MIM 606368) cluster on chromosomeThe American11, e.g., rs180327 (p ¼ 8 3 107), rs2072560 (p ¼ 1 3
1012), and rs9804646 (p ¼ 1 3 106). We also validated
the association of ABCG8 with LDL-C (rs4299376; p ¼
9 3 1010). This SNP is in complete LD (r2 ¼ 1) with the
previously reported ABCG8 (MIM 605460) rs654471322
and our results extend the association of ABCG8 to apoB
(p ¼ 8 3 108).
A total of 73 SNPs in 10 genes or clusters (Table S3C) were
associated with TG levels, including SNPs in GCKR (MIM
600842) (rs1260326, p ¼ 2 3 107),22,24,25 BAZ1B (MIM
605681)/MLXIPL (MIM 605678) (rs17145713, p ¼ 6 3
105),26 and LPL (MIM 609708) (rs285, rs331, and
rs3289; ranging from p ¼ 3 3 106 to 2 3 1011). There
were also highly signiﬁcant associations with the chr 11
APOA5 cluster (e.g., r651821, p ¼ 9 3 1021).Journal of Human Genetics 85, 628–642, November 13, 2009 631
Five genes/regions were associated with both HDL-C
(71 SNPs at p < 105) and apoAI (49 SNPs at p < 105)
(Tables S3D and S3E). SNPs in CETP exhibited the most
signiﬁcant associations, including rs3764261 (p ¼ 8 3
1036) and rs17231506 (p ¼ 1.4 3 1019) for HDL-C and
apoAI, respectively, as did SNPs in LPL (e.g., rs301, p ¼
9.0 3 1011 and 4 3 106, respectively), as well as several
SNPs in LIPC (MIM 151670) (e.g., rs261342, p ¼ 6 3
108 and 3 3 1011, respectively). The strongest determi-
nants of apoB and apoAI, individually, were also the deter-
minants of the apoB/apoAI ratio, analyzed as a separate
phenotype.
New Association Signals
To conduct a sweep for previously unreported genes/
regions, we undertook an in silico analysis of 48 SNPs asso-
ciated with LDL-C, HDL-C, or TG with p values of %104
in WH-II in the BWHHS, BRIGHT, ASCOT, and NORDIL
studies and pooled the effect estimates by meta-analysis.
For two of these SNPs, rs3184504 and rs1049817, we also
tested for replication in NPHSII. Ten SNPs including
rs12467409 (BMPR2 [MIM 600799], chr 2), rs3184504
(SH2B3 [MIM 605093], chr 12), seven SNPs in BCL3/
PVRL2 on chr 19 upstream of APOE/TOMM40, and
rs1529729 (SMARCA4 [MIM 603254], upstream of LDLR,
chr 19) were associated with LDL-C and yielded meta-anal-
ysis p value< 105 (Figure 2). Two SNPs associated with TG
levels, rs2314028 in GMIP (MIM 609694) and a GTF3C2
(MIM 604883) rs1049817, yielded p values > 105 in
meta-analyses.
Reﬁnement of Association Signals via Variable
Selection
In the presence of multiple signals of association in regions
of LD, we undertook a stepwise regression analysis by using
the AIC to identify independently predictive SNPs for each
associated gene or region (Figures 3–5; Figures S3A and S3B;
and Table S6).
We detected additional predictors of association in the
region of chr 19 that includes SNPs in BCL3, PVRL2,
TOMM40, and APOE-C1-C2-C4, even after including the
established functional cSNPs in APOE (rs429358 and
rs7412) in the model (see Table S6 column ‘‘stepAIC’’).
Four of the PVRL2 SNPs exhibiting association with
LDL-C in the meta-analyses were retained as independent
predictors, as was BMPR2 rs12467409 on chr 2 (Figure 2).
However, SMARCA4 rs1529729 (associated with LDL-C)
located in close proximity to the LDLR on chr 19 and
GTF3C2 rs1049817 (associated with TG), located close to
GCKR, were not retained after variable selection.
Spectrum of Effects of Associating SNPs with Multiple
Lipid and Lipoprotein Traits
The lipid-related traits we studied are intercorrelated
(Figure S2), but the extent of overlap of the genetic associ-
ations across these phenotypes has not been extensively
addressed. We summarize by means of a heat plot the spec-632 The American Journal of Human Genetics 85, 628–642, Novemtrum of associations of the 195 SNPs that passed the
p value threshold of 105 (Figure 6). Several distinct pro-
ﬁles of association emerged. For SNPs in PCSK9, CELSR2,
APOB, LDLR, HMGCR, and the APOE gene cluster, the
predominant associations were with both LDL-C and
apoB but not with TG, HDL-C, or apoAI. By contrast,
SNPs in CETP and LIPC were predominantly associated
with HDL-C and apoAI but less so or not at all with
LDL-C, apoB, or TG, whereas SNPs in LPL and APOA5
were associated most strongly with TG and HDL-C.
Effect Size
The proportion of the variance explained by each single
SNPs was typically <5%. However, the overall variance
jointly explained by the common associating alleles was
14.6% for LDL-C, 14.7% for apoB, 9.5% for HDL-C, 6.1%
for apoAI, and 7.8% for TG, which, in most cases, was
greater than the variance explained by age and gender
(Figures 7A–7C). When assessed in this way, SNPs in the
APOE gene cluster, LDL-R, and APOB emerged as the major
contributors to variance in both LDL cholesterol and apoB,
and the CETP and LIPC genes as the major contributors to
both HDL cholesterol and apoAI. SNPs in APOA5, LIPC,
and BAZ1B/MLXIPL were the major genetic inﬂuences on
TG levels.
Assessment of effect size, based solely on the proportion
of variance explained, can underemphasize the effect of
variants that have a substantial effect on a trait, but which
are rare in a population.
For LDL-C, the SNP having the largest individual effect
was a low-frequency cSNP (rs11591147; L46R) in PCSK9
(MAF 0.016)9 with rare allele homozygotes having LDL-C
levels around 32% (1.4 mmol/l) lower than common allele
homozygotes (Table S6). For the LDLR SNP with the stron-
gest effect, rs1724820, there was a 0.59 mmol/l mean
difference in LDL-C between homozygous individuals
whereas for LDLR rs2228671 (C27C, an association previ-
ously identiﬁed in GWAS27), there was a 0.24 mmol/l
mean difference between homozygous subjects. Overall,
genetic effects on apoB were proportionately similar to
those seen with LDL (Table S6).
Common CETP SNPs had the largest individual effects
for HDL and apoAI (0.1–0.2 mmol/l and 0.07–0.17 g/l,
respectively, in comparison to homozygous subjects).
Similar effect sizes were seen for SNPs in the APOA5 cluster
with HDL-C, with rs651821 having the largest TG-raising
effect of 0.5 mmol/l, reﬂecting a 20% difference in levels
in rare versus common homozygotes. In this study, GCKR
rs1260326 (P446L)22,24,25 was associated with a TG-raising
effect of approximately 6% and the chr 7 locus BAZ1B/
MLXIPL26 SNP rs17145713 was associated with an 8%
TG-lowering effect.
We derived trait-speciﬁc gene scores comprising 21 SNPs
for LDL-C, 19 for apoB, 15 for HDL-C, 10 for apoAI, 16 for
TG, and 18 for apoB/apoAI. The gene score distribution
and effect on trait levels are shown in Figures 8A and 8B
for LDL-C and TG and Table S5 and Figures S4A–S4D forber 13, 2009
Figure 2. Forest Plots for Fixed Effects Meta-analyses for Previously Unreported Association Signals
Forest plots for ﬁxed effects meta-analyses of beta-coefﬁcients associated with LDL-C.The American Journal of Human Genetics 85, 628–642, November 13, 2009 633
Figure 3. Haploview Plots of SNPs Showing Significant Associations with LDL-C before and after Variable Selection in Whitehall II
Haploview plots for LDL-C-associated SNPs signiﬁcant by univariate analysis (at p< 105) and those retained after variable selection (red
boxes). Bar charts show the –log10 p value for each SNP from the univariate analysis, with those in red corresponding to the values for
SNPs retained after variable selection. For LDL-C and the chr 19 APOE cluster, orange boxes designate SNPs that were not retained after
inclusion in the model of the APOE E2, E3, E4 variants that had been previously genotyped in WH-II.26HDL-C, apoAI, apoB, and apoB/apoAI. Individuals in the
highest 5% of the distribution of the respective traits had
a higher predicted LDL-C (by 1.1 mmol/l, equivalent to
approximately 1.1 standard deviations), a higher predicted
apoB concentration (by 0.3 g/l [0.21 standard deviations]),
and a higher predicted TG (by 0.61 mmol/l [0.17 standard
deviations]) than those in the lowest 5% of the distribu-
tion. The corresponding differences were 0.30 mmol/l
(0.12 standard deviations) for HDL-C and 0.25 g/l (0.11
standard deviations) for apoAI. The odds ratio for occu-
pancy of the extreme 10% of the trait distribution at
different cut points of the respective gene score distribu-
tions are shown in Figures 8A and 8B and Figures S4A–
S4D. For example, individuals at or above the 95th centile
of the gene score distribution of LDL-C-raising SNPs had
a 17-fold higher risk of occupying the top 10% of the
LDL-C distribution, compared with individuals below the
95th centile.634 The American Journal of Human Genetics 85, 628–642, NovembDiscussion
Loci Affecting LDL Cholesterol and ApoB
We identiﬁed an almost complete overlap of genes and
regions inﬂuencing LDL-C and apoB concentrations,
with similar inﬂuence on the proportion of the explained
variance in the respective traits. The loci associated with
LDL-C overlapped with those identiﬁed by prior GWAS.
The locus having the greatest effect on LDL-C and apoB
variance was the APOE cluster on chr 19, which had been
identiﬁed to be associated with LDL-C in GWASs.22,23
Two SNPs, rs429358 and rs7412, together deﬁne the
common APOE E2, E3, E4 genotypes, which are in essence
haplotypes deﬁned by the base changes altering residues
112 and 158 of the encoded protein, apoE. Although
rs7412 is present on the chip, rs429358 failed the design
and is not on the chip. Thus, with genotype data for
only one SNP, these common APOE genotypes could noter 13, 2009
Figure 4. Haploview Plots of SNPs Showing Significant Associations with HDL-C before and after Variable Selection in Whitehall II
Haploview plots for HDL-C-associated SNPs signiﬁcant by univariate analysis (at p< 105) and those retained after variable selection (red
boxes). Bar charts show the –log10 p value for each SNP from the univariate analysis, with those in red corresponding to the values for
SNPs retained after variable selection.be determined. However, both SNPs had been typed previ-
ously in WH-II28 and when they were included in the
regression model, three other SNPs in the APOE region
were no longer retained as independent predictors. This
suggests that the well-studied APOE variants that alter
amino acid residues 112 and 158 of apoE, and which are
known to affect receptor-binding and LDL-C catabolism
(reviewed in 29), explain much of the effect.
The loci having the next largest effect are those encoding
the LDL receptor and ApoB, proteins that play key roles in
LDL-C catabolism, as the primary receptor, and the ligand
for LDL clearance. Six loci have similar or smaller effects
including PCSK9 and HMGCoA reductase (HMGCR), the
rate-limiting enzyme in cholesterol biosynthesis, which
is already the target for lipid-lowering statins. Variants in
HMGCR were associated with effects on both LDL-C and
apoB levels. The SNP, rs12916, which remained after
variable selection, is in LD (r2 ¼ 0.84) with, and likely to
be marking, a recently identiﬁed functional variant,
rs3846662, which in vitro resulted in 2.2-fold lowerThe AmericanHMGCR expression and was associated with differences
LDL-C levels.30 Concerning the SORT1/CELSR2/PSRC1
locus, data from liver expression studies in mice showed
that Sort1 and Celsr2 were negatively correlated with
LDL-C, in agreement with human ﬁndings, but Psrc1
expression was positively correlated to LDL-C.31 Further
conﬁrmation that SORT1/CELSR2 form a subnetwork
comes from GO annotation that identiﬁes them as being
involved in the process of cell surface receptor-linked
signal transduction, whereas PSRC1 is more likely to be
involved in cell cycle pathways.31 A recent detailed study
in more than 18,000 individuals of the SORT1 SNP,
rs599839, conﬁrmed its association with decreased LDL-C
and lower risk of coronary heart disease and this was sup-
ported by expression array analysis and in vitro studies,
demonstrating that the consequence of increased sortilin
expression was to enhance LDL uptake into cells.32
Although not entirely excluding some cooperativity
between SORT1 and CELSR2, this strongly suggests that
SORT1 is involved in LDL-C determination.Journal of Human Genetics 85, 628–642, November 13, 2009 635
Figure 5. Haploview Plots of SNPs Showing Significant Associations with Triglycerides before and after Variable Selection in
Whitehall II
Haploview plots for triglyceride-associated the SNPs signiﬁcant by univariate analysis (at p< 105) and those retained after variable selec-
tion (red boxes). Bar charts show the –log10 p value for each SNP from the univariate analysis, with those in red corresponding to the
values for SNPs retained after variable selection.All the above genes that showed association with LDL-C
and, in the current study, with apoB levels have also
been associated with coronary heart disease (CHD) risk.23
These ﬁndings further endorse the causal role of LDL-C
in CHD and suggest additional therapeutic targets for
LDL reduction.
Loci Affecting HDL-C and ApoAI
CETP, encoding cholesteryl ester transfer protein, ex-
hibited the strongest associations with HDL-C and apoAI,
conﬁrming GWASs ﬁndings,22,23 with 6 of the 35 CETP
SNPs being retained after variable selection, suggesting
the existence of multiple functional SNPs in CETP. The
intronic SNP rs708272 (TaqIB), not thought to be func-
tional and the subject of many candidate gene studies,33
was strongly associated with both HDL-C and apoAI levels636 The American Journal of Human Genetics 85, 628–642, Novembin univariate analyses, but was not retained after variable
selection. SNP rs5880 (P390A), which is retained in the
model, may affect CETP activity directly, as shown by the
fact that it causes protein backbone strain.
Loci Affecting Triglycerides
The chromosome 11 gene cluster comprising BUD13/
ZNF259/APOA5/APOA4/APOC3/APOA1 contained mul-
tiple SNPs associated with TG levels. The locus contributes
38% of the genetic variance of TG as well as explaining
11% of HDL-C, 4% of LDL-C, and 10% of apoB genetic
variance. GCKR,9,24,25 BAZ1B/MLXIPL,34 and TRIB19,23
all recent GWAS hits, were replicated, and together con-
tribute 22% of the explained genetic variance of TG.
However, several loci associated with these lipid traits
that had been identiﬁed by GWAS studies did not reacher 13, 2009
our level of statistical signiﬁcance and these are presented
in Table S4.
Newly Identiﬁed Gene Regions
Of the 48 SNPs signiﬁcant at%104 identiﬁed in WH-II, in
regions not previously associated with these traits, SNPs
from 4 regions retained association with LDL-C at %105
when examined by meta-analysis across the ﬁve studies
Figure 6. Heat Plot of the Associations of
the 195 Significant SNPs across All the
Lipid and Lipoprotein Variables Analyzed
and >12,500 individuals. The SNP
rs3184504, a nonsynonymous variant
in SH2B3 (R262W), previously shown
to be associated with myocardial
infarction and asthma risk, as well as
with eosinophil count, type 1 diabetes
(MIM 222100), celiac disease (MIM
212750), and more recently blood
pressure,35–38 was associated with
LDL-C in WH-II at p ¼ 7 3 105, and
at p ¼ 2.17 3 106 in the pooled anal-
ysis of more than 15,000 subjects. It
seems surprising this variant should
not have been identiﬁed previously
by pooled analyses of GWAS of LDL-C
that have included >48,000 individ-
uals in which this SNP was directly
typed or imputed,22,24,27 because
coverage of this region has been exten-
sive on SNP platforms employed by
prior GWAS (see Figure S7A). We
observed evidence of a possible effect
modiﬁcation by gender, i.e., associa-
tion in BWHHS (all women) and a
null association in NPHS-II (all men).
However, both the marginal associa-
tion of this SNP with LDL-C, as well
as the possibility of a gender interac-
tion, will require further validation
and replication. It cannot be excluded,
at this point, that this is a chance
ﬁnding, and it is essential that further
studies are conducted to conﬁrm or
refute this association. Nevertheless,
in the present analysis, the direction
of effect and point estimates were
consistent across studies. As outlined
by Manolio,7 even in the three recent
large GWAS for lipid genes,22,24,27
whereas 18 loci were common to all
three studies, up to six loci were
common to only two of the three
studies, and between three and eight
loci were unique to each study. Similarly, in the two recent
GWASmeta-analyses for blood pressure loci,37,38 only three
loci were common to both studies, while ﬁve additional loci
were unique to each of the twometa-analyses. One explana-
tion could be context-dependent effects that could
contribute to the heterogeneity between studies. Alterna-
tively, it could be an issue of power despite the large number
of individuals genotyped.The American Journal of Human Genetics 85, 628–642, November 13, 2009 637
SNPs in PVRL2 upstream of APOE, and in SMARCA4
upstream of LDLR, associated with LDL-C and retained in
variable selection, also showed consistent association
with LDL-C in the meta-analysis (Figure 2), suggesting
a potential independent signal arising from these genes.
The comparative coverage of these regions by GWAS and
the Cardiochip is presented in Figures S5B and S5C. As
with coverage of SH2B3, GWAS coverage of these loci
were good so it is unclear why these regions have not
been previously detected as affecting lipid traits.
The BMPR2 association with LDL-C was conﬁrmed by the
meta-analysis (Figure2).This locus (seeTableS5Dforcompar-
ative coverage toGWAS chips) encodes bonemorphogenetic
protein receptor, type II. Mutations in this gene have been
associated with primary pulmonary hypertension (MIM
178600),39 but links with LDL-C need further validation.
Patterns of Association across the Five Lipid,
Lipoprotein, and Apolipoprotein Phenotypes
Although the panel of index SNPs were identiﬁed on the
basis of associationwith a single lipid or lipoprotein pheno-
type, many SNPs were associated with more than one trait.
A
B
C
Figure 7. Pie Charts Showing the Contri-
bution of SNPs to the Genetic Variance of
Lipid, Lipoprotein, and Apolipoprotein
Traits
Contributionof SNPs retainedafter variable
selection to the genetic variance of the (A)
LDL-C and ApoB, (B) HDL-C and ApoAI,
and (C) triglycerides. Inset in each ﬁgure is
shown as a proportion of the total variance
of the trait compared to the variance of
the trait explained by age and gender.
One potential explanation for the
joint signals of association could
simply be the high degree of correla-
tion between traits.40 Although this
is a possibility for associations of
a given SNP with LDL-C and its major
apolipoprotein constituent apoB, and
for HDL-C with apoAI, this seems an
unlikely explanation for the joint
association of some SNPs with several
lipid traits. These distinct association
patterns provide circumstantial evi-
dence for distinct biological mecha-
nisms that could be informative for
the understanding of lipid and lipo-
protein metabolism and on the likely
consequences of modifying the target
proteins pharmacologically.
Effect Size of Common Alleles
In the current analysis, indepen-
dently associating SNPs at each locus
jointly explained between 6% and
15% of the variance in these traits. It should be noted,
however, that this will be an overestimate because of the
potential bias introduced by selecting SNPs and estimating
effect sizes within the same data set, so replication in an
independent data set is required to validate this estimate.
Additional variants (including common or rare SNPs and
structural variants) or context-dependent genetic effects
(e.g., gene-gene and gene-environment interactions) are
likely to contribute in whole or part to the remaining
unexplained variance. There is already a precedent for
rare variants contributing to the variance in LDL41,
HDL,42 and TG.43
However, variance is only one of a number of metrics of
effect, and the gene score analysis provides evidence that
carrying multiple common trait-modifying alleles can
make an important contribution to the between-indi-
vidual differences in trait levels. We found a >1.0 mmol/L
difference in LDL-C between individuals at the 5%
extremes of the distribution of the number of LDL-modi-
fying alleles carried, an effect that is similar in size to that
seen with the commonly used doses of statins in CHD
prevention. This suggests that one in every 20 individuals638 The American Journal of Human Genetics 85, 628–642, November 13, 2009
A B
Figure 8. Frequency Distribution of the Gene Count Scores for LDL-C and Triglycerides
Frequency distribution of the gene count score for (A) LDL-C and (B) TG with the ﬁtted line representing the effect of gene score on trait
level, with increasing score. Below each gene score histogram is a plot of the odds ratio for being in either the top or bottom 10% of the
trait distribution at different cut points of the respective gene score below. Themedians (interquartile ranges) of the gene counts were 27
(25–30) for LDL-C and 13 (11–14) for TG.in the population could be at substantially different risk of
CHD by virtue of their complement of common LDL-
modifying alleles, though this ﬁnding does not necessarily
argue that typing of such panel of alleles would be useful in
risk prediction. Moreover, the odds of being in the top 10%
of the trait distribution increased sharply with the number
of trait-modifying alleles carried, suggesting that occu-
pancy of the upper ranks of the trait distribution of blood
lipids is achieved in some individuals by carriage of a small
number of rare alleles, e.g., in PCSK9 of large effect, and in
others by carriage of a larger repertoire of common alleles
of modest effect.
For the apoB/apoAI ratio, the odd ratio for individuals at
or above the 95th centile of the gene score is 13-fold higher
if they are in the top 10% of the apoB/apoAI than the rest.
This is comparable to that for LDL-C and supports the
argument that measurement of apoB and apoAI, expressed
as the ratio deﬁning pro- and antiatherogeneic particles,
are as predictive and more reliable in their measurement,
than LDL-C levels that are usually calculated.6
Relevance of the Current Findings for Future Research
and Clinical Application
Whole-genome analysis has produced a surge in our
understanding of the genetic contribution to interindi-The Americanvidual differences in the blood lipids but we are still in
the discovery phase and the challenge of identifying causal
variants at each identiﬁed locus remains. Although denser
genotyping at loci of interest can contribute to the ﬁne
mapping efforts, and our analysis indicates that multiple
predictive SNPs (marking causal sites) might be a common
feature of the genetic architecture of lipid phenotypes,
additional efforts directed at resequencing individuals
carrying the relevant haplotypes will be required.
The small individual contribution of common alleles to
the variance in quantitative traits has led to concerns that
the translational potential of recent GWAS ﬁndingsmay be
limited. However, in the case of rarer SNPs that make
a minor contribution to the proportion of the variance
explained, the difference in trait levels per allele can be
substantial. Moreover, as the gene score plots illustrate,
differences in LDL cholesterol levels of a magnitude seen
from the use of standard doses of statins5 can be observed
in individuals at opposite extremes of a gene score distribu-
tion for common alleles.
Furthermore, because genotype is randomly allocated
and invariant, genetic associations provide unique insight
on causal pathways, and the ﬁndings can be considered
as a type of natural randomized trial. It is notable, for
example, that the effects of HMGCR and CETP SNPsJournal of Human Genetics 85, 628–642, November 13, 2009 639
identiﬁed here closely mimic the effects of HMGCR44 and
CETP inhibitors45 on lipid levels seen in clinical trials
(albeit with a smaller effect size), suggesting that genetic
studies might be helpful in modeling the effects of poten-
tial lipid-lowering therapies during the process of drug
development. Cholesterol lowering, whether by pharma-
cotherapeutic or lifestyle modiﬁcation, has been suspected
of increasing some adverse events, such as depression, with
observational studies ﬁnding associations between low
cholesterol and high depression.46 Genetic variants can
be utilized in a Mendelian randomization framework47
and the availability of multiple independent related vari-
ants allows several of the key assumptions of this method
to be interrogated. Taken together, these observations
suggest that effect size per se is not the major indicator
of potential translational utility of the recent genetic
advances.
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